Genetic Investigation of Solid Tumors Cohort

Overview

The objective of this study is to obtain blood samples, solid tumor and/or benign hyperplasia samples to learn more about genetic differences that are linked to the formation of solid tumors.

Study Type

  • Study Type: Observational
  • Study Design
  • Study Primary Completion Date: May 2014

Detailed Description

Recent studies in human genetics have discovered several intervals in the human genome containing inherited variants that are statistically associated with the propensity to develop solid tumors. Even though it has been firmly established that if an individual carries these DNA variants they have an increased chance of developing a solid tumor the underlying biological mechanisms for most of these associations are largely unknown. In addition to inherited DNA variants that are associated with the development of solid tumors it is well established that during the development and growth of solid tumors the DNA in these cancer cells undergo somatic changes (mutations). These somatic DNA changes have been studied over the past decade and frequently are specific chromosomal translocations and amplifications associated with the development of particular solid tumors. In some instances, examining the chromosomal translocation and amplification has lead to the discovery of proteins contributing to solid tumor pathology. the human 8q24 interval that has strong genetic associations with solid tumor development has also been noted as frequently amplified in solid tumors and serves as a predictor of poor survival in prostate cancers.

Arms, Groups and Cohorts

  • Solid tumors
    • Participants 18 years of age or older who have been diagnosed with a solid tumor or benign hyperplasia that needs surgical removal will be included in this study.

Clinical Trial Outcome Measures

Primary Measures

  • Solid tumor biological insights
    • Time Frame: Study completion
    • Obtain blood samples, solid tumor and/or benign hyperplasia samples, and in some instances normal tissue in order to gain biological insights into cancer (solid tumors) through population genetics and genomics.

Participating in This Clinical Trial

Inclusion Criteria

1. Age 18 years or older 2. Eligible to have their blood drawn 3. Be reliable, cooperative and willing to comply with all protocol-specified procedures 4. Able to understand and grant informed consent 5. Diagnosis of a solid tumor Exclusion Criteria:

1. Has a significant chronic medical condition which would potentially confound interpretation of the individual's phenotype. 2. Treatment with any investigational agents or devices within thirty days preceding enrollment in the study. 3. Been administered or taken any CNS sedatives or depressants in the 12 hours prior to informed consent process

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Scripps Translational Science Institute
  • Provider of Information About this Clinical Study
    • Principal Investigator: Eric Topol, MD, Director – Scripps Translational Science Institute
  • Overall Official(s)
    • James Mason, MD, Principal Investigator, Scripps Health

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.